StreetInsider.com News Articles

MannKind Data at HFSA 2026 Highlights New Evidence Supporting Furoscix ReadyFlow™ for the Outpatient Management of Edema in Heart Failure (HF) and Chronic Kidney Disease (CKD)

Fri, 09 Oct 2026 20:00:00 -0400

New analyses on Furoscix ReadyFlow PK/PD performance delivered via an autoinjector demonstrated comparable urine output to IV furosemide
Consistent bioavailability, diuresis and natriuresis across injection sites support flexible administration in clinical practice
Cross-study analysis demonstrates comparable diuretic and natriuretic responses between Furoscix ReadyFlow and Furoscix^® (furosemide) On-body Infusor, supporting a seamless transition to ReadyFlow
Data presentations build on the July 2026 FDA approval and U.S. launch of Furoscix ReadyFlow, the first and only autoinjector delivering IV-equivalent diuretic therapy for heart failure- and CKD-related edema (fluid overload)

WESTLAKE VILLAGE, Calif., Oct. 09, 2026 (GLOBE

MannKind Data at HFSA 2026 Highlights New Evidence Supporting Furoscix ReadyFlow™ for the Outpatient Management of Edema in Heart Failure (HF) and Chronic Kidney Disease (CKD)

Fri, 09 Oct 2026 20:00:00 -0400

New analyses on Furoscix ReadyFlow PK/PD performance delivered via an autoinjector demonstrated comparable urine output to IV furosemide
Consistent bioavailability, diuresis and natriuresis across injection sites support flexible administration in clinical practice
Cross-study analysis demonstrates comparable diuretic and natriuretic responses between Furoscix ReadyFlow and Furoscix^® (furosemide) On-body Infusor, supporting a seamless transition to ReadyFlow
Data presentations build on the July 2026 FDA approval and U.S. launch of Furoscix ReadyFlow, the first and only autoinjector delivering IV-equivalent diuretic therapy for heart failure- and CKD-related edema (fluid overload)

WESTLAKE VILLAGE, Calif., Oct. 09, 2026 (GLOBE

MannKind (MNKD) PT Lowered to $5 at Truist Securities

Wed, 07 Oct 2026 07:14:07 -0400

Truist Securities analyst Greg Renza lowered the price target on MannKind (NASDAQ: MNKD) to $5.00 (from $6.00) while maintaining a Buy rating.

Form 4 MANNKIND CORP For: Sep 25 Filed by: Binder Steven B.

Mon, 28 Sep 2026 20:26:00 -0400

si-local-file:///var/storage/secattach/20260928/27115893.html

Form 144 MANNKIND CORP Filed by: Binder Steven B.

Fri, 25 Sep 2026 16:18:00 -0400

si-local-file:///var/storage/secattach/20260925/27107615.html

Form 4 MANNKIND CORP For: Sep 10 Filed by: Binder Steven B.

Mon, 14 Sep 2026 20:00:00 -0400

si-local-file:///var/storage/secattach/20260914/27059740.html

MannKind (MNKD) Reiterated at Overweight by Cantor Fitzgerald on Positive MNKD-201 Ph1 Data

Fri, 11 Sep 2026 07:30:35 -0400

Cantor Fitzgerald analyst Olivia Brayer reiterated an Overweight rating and $8.00 price target on MannKind (NASDAQ: MNKD).

The analyst commented, "MannKind has had a busy year, to say the least. They announced positive Ph1b data for inhaled nintedanib (MNKD-201), received approval for the Furoscix autoinjector, and launched Afrezza in type 1 diabetes. Amongst these, we view their opportunity set in IPF as the most compelling part of the long-term thesis (they now have 3 different shots on goal in IPF with Tyvaso DPI, ralinepag DPI, and inhaled nintedanib). And they just announced an update to their phase 2 MNKD-201 study for

MannKind (MNKD) Reiterated at Overweight by Cantor Fitzgerald on Positive MNKD-201 Ph1 Data

Fri, 11 Sep 2026 07:29:07 -0400

Cantor Fitzgerald analyst Olivia Brayer reiterated an Overweight rating and $8.00 price target on MannKind (NASDAQ: MNKD).

Form 144 MANNKIND CORP Filed by: Binder Steven B.

Thu, 10 Sep 2026 16:43:00 -0400

si-local-file:///var/storage/secattach/20260910/27049082.html

MannKind and Rose Pharma agree to develop inhaled GLP-1 therapy

Wed, 09 Sep 2026 06:31:20 -0400

MannKind Corporation (Nasdaq: MNKD) and Rose Pharma Inc. have entered into a worldwide licensing and collaboration agreement to develop ROSE-010 Technosphere, an investigational inhaled GLP-1 receptor agonist intended for weight management, according to a press release from the companies.

Under the agreement, Rose Pharma received an exclusive, worldwide license to use MannKind's proprietary Technosphere dry-powder inhalation technology to develop and commercialize ROSE-010 Technosphere. MannKind will provide pharmaceutical development and manufacturing support through the completion of a Phase 1b clinical study.

In exchange, MannKind will receive an equity interest in Rose Pharma, the right to receive royalties on potential future net sales of

MannKind and Rose Pharma Inc Enter Licensing and Collaboration Agreement to Develop an Inhaled Rapid-Acting, Short-Duration GLP-1 for Weight Management

Wed, 09 Sep 2026 06:30:00 -0400

Collaboration combines Rose Pharma investigational rapid-acting GLP-1 receptor agonist with MannKind’s Technosphere^® inhalation technology
MannKind to receive an equity interest and potential royalties while providing pharmaceutical development and manufacturing support through completion of a Phase 1b clinical study

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Sept. 09, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a biopharmaceutical company focused on developing innovative, patient-centric therapies for chronic diseases, and Rose Pharma Inc. (Rose Pharma) today announced that they have entered into a worldwide licensing and collaboration agreement to develop ROSE-010 Technosphere for weight management. ROSE-010 is an investigational, rapid-acting

MannKind and Rose Pharma Inc Enter Licensing and Collaboration Agreement to Develop an Inhaled Rapid-Acting, Short-Duration GLP-1 for Weight Management

Wed, 09 Sep 2026 06:30:00 -0400

Collaboration combines Rose Pharma investigational rapid-acting GLP-1 receptor agonist with MannKind’s Technosphere^® inhalation technology
MannKind to receive an equity interest and potential royalties while providing pharmaceutical development and manufacturing support through completion of a Phase 1b clinical study

MannKind to Present at Upcoming Investor Conferences

Wed, 02 Sep 2026 08:30:00 -0400

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), today announced that members of the MannKind management team will present at the following upcoming investor conferences:

Cantor Global Healthcare Conference (New York, NY)
Fireside Chat, Thursday, September 10, 2026, at 11:30 a.m. ET

H.C. Wainwright 28th Annual Global Investment Conference (New York, NY)
Fireside Chat, Tuesday, September 15, 2026, at 9:30 a.m. ET

Links to the live audio webcasts of the presentations will be available on MannKind Corporation’s website at: https://investors.mannkindcorp.com/events-and-presentations. A recorded version will also be available

MannKind to Present at Upcoming Investor Conferences

Wed, 02 Sep 2026 08:30:00 -0400

Cantor Global Healthcare Conference (New York, NY)
Fireside Chat, Thursday, September 10, 2026, at 11:30 a.m. ET

H.C. Wainwright 28th Annual Global Investment Conference (New York, NY)
Fireside Chat, Tuesday, September 15, 2026, at 9:30 a.m. ET

Form 8-K MANNKIND CORP For: Aug 21

Fri, 21 Aug 2026 16:10:00 -0400

si-local-file:///var/storage/secattach/20260821/26961477.html

Form 8-K MANNKIND CORP For: Aug 21

Fri, 21 Aug 2026 16:10:00 -0400

si-local-file:///var/storage/secattach/20260821/26961477.html

Form 424B7 MANNKIND CORP

Fri, 21 Aug 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260821/26961405.html

Form 424B7 MANNKIND CORP

Fri, 21 Aug 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260821/26961405.html

Form SCHEDULE 13G MANNKIND CORP Filed by: Rubric Capital Management LP

Fri, 14 Aug 2026 16:08:00 -0400

si-local-file:///var/storage/secattach/20260814/26930193.html

Form SCHEDULE 13G MANNKIND CORP Filed by: Rubric Capital Management LP

Fri, 14 Aug 2026 16:08:00 -0400

si-local-file:///var/storage/secattach/20260814/26930193.html

Form 4 MANNKIND CORP For: Aug 07 Filed by: Binder Steven B.

Mon, 10 Aug 2026 20:45:00 -0400

si-local-file:///var/storage/secattach/20260810/26899695.html

Form 4 MANNKIND CORP For: Aug 07 Filed by: Binder Steven B.

Mon, 10 Aug 2026 20:45:00 -0400

si-local-file:///var/storage/secattach/20260810/26899695.html

Form 144 MANNKIND CORP Filed by: Binder Steven B.

Fri, 07 Aug 2026 16:39:00 -0400

si-local-file:///var/storage/secattach/20260807/26891739.html

Form 144 MANNKIND CORP Filed by: Binder Steven B.

Fri, 07 Aug 2026 16:39:00 -0400

si-local-file:///var/storage/secattach/20260807/26891739.html

H.C. Wainwright Reiterates Buy Rating on MannKind (MNKD)

Thu, 06 Aug 2026 06:57:54 -0400

H.C. Wainwright analyst Brandon Folkes reiterated a Buy rating and $10.00 price target on MannKind (NASDAQ: MNKD).

The analyst commented: "FDA approval and launch of pediatric Afrezza, FDA approval of FUROSCIX ReadyFlow and clean Phase 1b tolerability data for nintedanib DPI/MNKD-201 in patients with IPF. The focus in 2H26 shifts from regulatory and clinical catalysts to commercial execution. MNKD reported a mixed but thesis-supportive 2Q26, with revenue modestly above consensus, although the composition of the beat was weighted toward manufacturing and collaboration revenue rather than the company’s promoted products. The commercial tailwinds from pediatric Afrezza and FUROSCIX ReadyFlow should become more